Contineum Therapeutics (CTNM) Change in Account Payables (2023 - 2026)
Contineum Therapeutics (CTNM) recorded quarterly Change in Account Payables of $490000.0 in Q1 2026, up 202.47% quarter-over-quarter from $162000.0 in Q4 2025, and down 73.28% on a YoY basis from $1.8 million in Q1 2025.
Contineum Therapeutics (CTNM) Change in Account Payables (2023 - 2026) Analysis & Trends
Contineum Therapeutics' Change in Account Payables history runs 4 years deep, the most recent figure standing at $490000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 73.28% year-over-year to $490000.0; the TTM figure through Mar 2026 stood at -$2.2 million (down 172.68% YoY), while the FY2025 annual figure was -$869000.0, down 176.16% from the prior year.
- Change in Account Payables was $490000.0 for Q1 2026 at Contineum Therapeutics, up from $162000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.8 million in Q1 2025 to a low of -$1.6 million in Q2 2025.
- Historically, Change in Account Payables has averaged $58615.4 across 4 years, with a median of $170000.0 in 2024.
- Biggest YoY gain for Change in Account Payables was 2720.0% in 2025; the steepest drop was 1067.06% in 2025.
- A 4-year view of Change in Account Payables shows it stood at -$625000.0 in 2023, then jumped by 160.48% to $378000.0 in 2024, then slumped by 57.14% to $162000.0 in 2025, then jumped by 202.47% to $490000.0 in 2026.
- The last three Change in Account Payables figures came in at $490000.0 (Q1 2026), $162000.0 (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -9.42 Mn |
| 10 | Contineum Therapeutics | 423.05 Mn | 423.05 Mn | - | 490,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 490,000.00 |
| Mar 31, 2026 | 490,000.00 |
| Dec 31, 2025 | 162,000.00 |
| Dec 31, 2025 | 162,000.00 |
| Sep 30, 2025 | -1.22 Mn |
| Sep 30, 2025 | -1.22 Mn |
| Jun 30, 2025 | -1.64 Mn |
| Jun 30, 2025 | -1.64 Mn |
| Mar 31, 2025 | 1.83 Mn |
| Mar 31, 2025 | 1.83 Mn |
| Dec 31, 2024 | 378,000.00 |
| Dec 31, 2024 | 378,000.00 |
| Sep 30, 2024 | 663,000.00 |
| Sep 30, 2024 | 663,000.00 |
| Jun 30, 2024 | 170,000.00 |
| Jun 30, 2024 | 170,000.00 |
| Mar 31, 2024 | -70,000.00 |
| Mar 31, 2024 | -70,000.00 |
| Dec 31, 2023 | -625,000.00 |
| Dec 31, 2023 | -625,000.00 |